PharmaDepth

Company profile

Moderna, Inc.

NASDAQ:MRNABiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (1)

AssetStageRevenueTrialsStatus
ELASOMERANphase1_2—10active

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (94)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06508320phase2completed2024-07-152025-09-25ModernaTX, Inc.A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT04528719phase1completed2020-09-302024-07-18ModernaTX, Inc.A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
NCT06147856phase1_2withdrawn2024-03-292026-08-10ModernaTX, Inc.A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
NCT04975893phase2completed2021-06-182026-01-19ModernaTX, Inc.A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
NCT05585632phase1completed2022-10-142024-02-28ModernaTX, Inc.A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

FDA applications (4)

ApplicationTypeApplicantProducts
BLA 125752BLAModernaTX, Inc.
BLA 125796BLAModernaTX, Inc.
BLA 125835BLAModernaTX, Inc.
BLA 125869BLAModernaTX, Inc.